                               SEQUENCE LISTING

<110> SPOTLIGHT THERAPEUTICS, INC.
 
<120> METHODS AND COMPOSITIONS FOR NUCLEIC ACID-GUIDED NUCLEASE CELL 
      TARGETING SCREEN

<130> S106638 1050WO

<140>
<141>

<150> 62/838,053
<151> 2019-04-24

<160> 26    

<170> PatentIn version 3.5

<210> 1
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 1
Ile Arg Arg Gly Ile Ser Arg Lys 
1               5               


<210> 2
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 2
Lys Arg Lys Arg Ala Val 
1               5       


<210> 3
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 3
Pro Lys Pro Lys Arg Gln Thr Lys Arg 
1               5                   


<210> 4
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 4
Arg Arg Arg Arg His Cys Asn Arg 
1               5               


<210> 5
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 5
Ile Pro Asp Pro Thr Gly Gln Ser 
1               5               


<210> 6
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 6
Ile Lys Arg Glu Arg Glu Asn Asp 
1               5               


<210> 7
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 7
Lys Lys Leu Gln Glu Gln Glu Lys Gln Gln Lys Val Glu Phe Arg Lys 
1               5                   10                  15      


Arg 
    


<210> 8
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 8
Gly Pro Asn Lys Lys Lys Arg Lys Leu 
1               5                   


<210> 9
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 9
Arg Arg Arg Arg Ala Ser Ala Pro Ile Ser Gln Trp Ser Ser Ser Arg 
1               5                   10                  15      


Arg Ser Arg 
            


<210> 10
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 10
Lys Leu Ala Leu Lys Leu Ala Leu Lys Ala Leu Lys Ala Ala Leu Lys 
1               5                   10                  15      


Leu Ala 
        


<210> 11
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 11
Phe Leu Pro Leu Ile Gly Arg Val Leu Ser Gly Ile Leu 
1               5                   10              


<210> 12
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 12
Cys Val Gln Trp Ser Leu Leu Arg Gly Tyr Gln Pro Cys Cys Val Gln 
1               5                   10                  15      


Trp Ser Leu Leu Arg Gly Tyr Gln Pro Cys 
            20                  25      


<210> 13
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polypeptide"

<400> 13
Arg Lys Lys Arg Lys Gly Ser Gly Ser Arg Lys Lys Arg Lys Gly Ser 
1               5                   10                  15      


Gly Ser Arg Lys Lys Arg Lys Gly Ser Gly Ser Arg Lys Lys Arg Lys 
            20                  25                  30          


<210> 14
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polypeptide"

<400> 14
Cys Val Gln Trp Ser Leu Leu Arg Gly Tyr Gln Pro Cys Gly Ser Gly 
1               5                   10                  15      


Ser Cys Val Gln Trp Ser Leu Leu Arg Gly Tyr Gln Pro Cys 
            20                  25                  30          


<210> 15
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polypeptide"

<400> 15
Lys Lys Arg Arg Arg Gly Ser Gly Ser Lys Lys Arg Arg Arg Gly Ser 
1               5                   10                  15      


Gly Ser Lys Lys Arg Arg Arg Gly Ser Gly Ser Lys Lys Arg Arg Arg 
            20                  25                  30          
   

<210> 16
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polypeptide"

<400> 16
Arg Lys Lys Arg Arg Gly Ser Gly Ser Arg Lys Lys Arg Arg Gly Ser 
1               5                   10                  15      


Gly Ser Arg Lys Lys Arg Arg Gly Ser Gly Ser Arg Lys Lys Arg Arg 
            20                  25                  30          
  

<210> 17
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 17
Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 
1               5                   10                  15      


Gly Gly Cys
        


<210> 18
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 18
Gly Arg Lys Arg Lys Arg Ser Gly Arg Lys Arg Lys Arg Ser Gly Arg 
1               5                   10                  15      


Lys Arg Lys Arg Ser Gly Arg Lys Arg Lys Arg Ser 
            20                  25              


<210> 19
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 19
Pro Arg Lys Lys Arg Gly Arg Pro Arg Lys Lys Arg Gly Arg Pro Arg 
1               5                   10                  15      


Lys Lys Arg Gly Arg Pro Arg Lys Lys Arg Gly Arg 
            20                  25              


<210> 20
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 20
Cys Val Gln Trp Ser Leu Leu Arg Gly Tyr Gln Pro Cys 
1               5                   10              


<210> 21
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Lys"

<220>
<221> VARIANT
<222> (3)..(3)
<223> /replace="Lys"

<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="Lys"

<220>
<221> SITE
<222> (1)..(9)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations 
      for variant positions"

<400> 21
Arg Lys Arg Arg Arg Gly Ser Gly Ser 
1               5                   


<210> 22
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      6xHis tag"

<400> 22
His His His His His His 
1               5       


<210> 23
<211> 9
<212> PRT
<213> Human immunodeficiency virus 1

<400> 23
Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1               5                   


<210> 24
<211> 12
<212> PRT
<213> Human immunodeficiency virus 1

<400> 24
Arg Gln Ala Arg Arg Asn Arg Arg Arg Arg Trp Arg 
1               5                   10          


<210> 25
<211> 7
<212> PRT
<213> Simian virus 40

<400> 25
Pro Lys Lys Lys Arg Lys Val 
1               5           


<210> 26
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 26
His His His His His His His His His His His His 
1               5                   10          


